Optimal loading dose for the initiation of warfarin: A systematic review

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  Heneghan, Carl ^a   Tyndel, Sally ^a   Bankhead, Clare ^a   Wan, Yi ^b   Keeling, David ^c   Perera, Rafael ^a   Ward, Alison ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; EMBASE; EVIDENCE BASED MEDICINE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MEDLINE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; AGE; AGED; BIBLIOGRAPHIC DATABASE; FEMALE; GENETICS; HEALTH CARE PLANNING; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; REVIEW;

AGE FACTORS; AGED; ANTICOAGULANTS; DATABASES, BIBLIOGRAPHIC; DRUG DOSAGE CALCULATIONS; FEMALE; HEALTH PLANNING GUIDELINES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; WARFARIN;

EID: 77950950908     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-18     Document Type: Article

References (30)

1. Atrial Fibrillation Investigators: Atrial Fibrillation AAS, Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Anticoagulation Study, Stroke Prevention in Atrial Fibrillation Study, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation: Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med 1994, 154:1449-1457. 10.1001/archinte.154.13.1449, 8018000, Atrial Fibrillation Investigators: Atrial Fibrillation AAS, Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Anticoagulation Study, Stroke Prevention in Atrial Fibrillation Study, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study.
2. Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. The Lancet 1994, 343:687-691. Stroke Prevention in Atrial Fibrillation Investigators.
3. Stroke Prevention in Atrial Fibrillation Investigators Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633-638. 10.1016/S0140-6736(96)03487-3, 8782752, Stroke Prevention in Atrial Fibrillation Investigators.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990, 323:1505-1511. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.
5. Fitzmaurice DA, Gardiner C, Kitchen S, Mackie I, Murray ET, Machin SJ. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. Br J Haematol 2005, 131:156-165. 10.1111/j.1365-2141.2005.05739.x, 16197444.
6. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009, 1940:1410-1416.
7. Ansell J. Long-term, secondary treatment of deep venous thrombosis: do we know the appropriate duration of treatment or therapeutic regimen?. Curr Hematol Rep 2004, 355-356.
8. Ansell JE. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management. Semin Vasc Med 2003, 261-270.
9. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.[see comment]. Ann Intern Med 1997, 126:133-136.
10. Harper P, Monahan K, Baker B. Warfarin induction at 5 mg daily is safe with a low risk of anticoagulant overdose: results of an audit of patients with deep vein thrombosis commencing warfarin. J Intern Med 2005, 1935:717-720.
11. Ageno W, Turpie AG, Steidl L, Ambrosini F, Cattaneo R, Codari RL, et al. Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. American Journal of Cardiology 2001, 88:40-44. 10.1016/S0002-9149(01)01582-X, 11423056.
12. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007, 136:26-29. 10.1111/j.1365-2141.2006.06379.x, 17116128.
13. Roberts GW, Druskeit T, Jorgensen LE, Wing LM, Gallus AS, Miller C, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. [see comment]. Australian & New Zealand Journal of Medicine 1999, 29:731-736.
14. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792. 10.1182/blood-2008-04-149070, 2630264, 18574025.
15. Shurin SB, Nabel EG. Pharmacogenomics--ready for prime time?. N Engl J Med 2008, 358:1061-1063. 10.1056/NEJMe0800801, 18322288.
16. Forde D, O'Connor M, Gilligan O. Potentially avoidable inpatient nights among warfarin receiving patients; an audit of a single university teaching hospital. BMC Research Notes 2009, 2:41. 10.1186/1756-0500-2-41, 2657894, 19284662.
17. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570. 10.1161/CIRCULATIONAHA.107.737312, 17989110.
18. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clinical Pharmacology & Therapeutics 2008, 83:460-470.
19. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. [see comment]. Arch Intern Med 1999, 159:46-48. 10.1001/archinte.159.1.46, 9892329.
20. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. [see comment]. Age & Ageing 2000, 29:31-34. 10.1093/ageing/29.1.31, 10690692.
21. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clinical Medicine & Research 2005, 3:137-145. 1237155, 16160068, 10.3121/cmr.3.3.137.
22. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. [see comment]. Ann Intern Med 2003, 138:714-719.
23. Quiroz R, Gerhard-Herman M, Kosowsky JM, DeSantis SM, Kucher N, McKean SC, et al. Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism. American Journal of Cardiology 2006, 98:535-537. 10.1016/j.amjcard.2006.02.063, 16893712.
24. Shine D, Patel J, Kumar J, Malik A, Jaeger J, Maida M, et al. A randomized trial of initial warfarin dosing based on simple clinical criteria. Thrombosis & Haemostasis 2003, 89:297-304.
25. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764. 10.1056/NEJMoa0809329, 2722908, 19228618.
26. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:160S-198S. 10.1378/chest.08-0670, 18574265.
27. Ansell J. Personalizing health care--is this the right time for warfarin?. J Gen Intern Med 2009, 1924:690-691.
28. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009, 1924:656-664.
29. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahe I, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 2005, 118:137-142. 10.1016/j.amjmed.2004.07.053, 15694897.
30. Cooper MW, Hendra TJ. Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people. Age Ageing 1998, 1927:655-656.